COMP <GO>
ABT vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Abbott Laboratories (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ABT 5
— ABBV 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ABBV
LAST: $104.57 (+1.88%) • MKT CAP: $180.95B
balance-sheet
4.36
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.40% | 70.20% | -13.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.90% | 29.00% | -17.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 33.3x | -14.90 | ABT | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 3.47% | +0.62 | ABT | /fcf-yield <GO> |
| Operating Margin | 18.20% | 24.60% | -6.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 14.70% | 6.90% | +7.80 | ABT | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 8.60% | -2.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 2.27% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 4.36 | 5.33 | -0.97 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ABT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.2 | 65.1 | -10.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.15 | -0.16 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.8x | 113.1x | -87.30 | ABT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $180.95B | $513.86B | -$332.91B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABT REV | ABBV REV | ABT GROSS % | ABBV GROSS % | ABT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.33B | $61.16B | 56.4% | 70.2% | $7.39B | $17.82B |
| FY 2024 | $41.95B | $56.33B | 55.4% | 70.0% | $6.35B | $17.83B |
| FY 2023 | $40.11B | $54.32B | — | — | $5.46B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABT // BETA 0.99
ABBV // BETA 1.15